306. MECHANISMS OF MYOCARDIAL FAILURE AND FIBROSIS

Minisymposium

Mon. 2:00 PM--San Diego Convention Center, Room 5A

Chaired: J. Schisler and T. Nevers

Cardiac Pathobiology

2:00 Introduction

2:10  306.1 The Role of miR-378*, miR-218 and miR-351 in Cardiac Hypertrophy S. Sadiq, F.J. Charchar, T. Crowley, L. Delbridge, S. Harrap, P. Lewandowski. Sch. of Med., Deakin Univ., Federation Univ. and Univ. of Melbourne, Australia


2:55  306.4 Activation of TRPVv1 by 12(S)-HpETE and 20-HETE Releases CGRP and Protects the Heart against the Cardiac Dysfunction Caused by LPS J. Chen, A.J.P. Hamers, M. Finsterbusch, C. Thiemermann, A. Ahluwalia. Barts and The London Sch. of Med. and Dent., Queen Mary Univ. of London

3:10  306.5 Pharmacological Inhibition of p38/MAPK Improves Cardiac Function in Cardiac-Specific Bag3-P209L Transgenic Mice S.C. Eaton, S. Takayama, T.N. Sidorova, K.T. Murray, M.S. Willis. Univ. of North Carolina at Chapel Hill, Boston Univ. and Vanderbilt Univ.


3:55  306.8 Fenofibrate Induces Cardiac Fibrosis in Mice Lacking the Co-chaperone and E3-Ubiquitin Ligase CHIP S. Ravi, M.S. Willis, P. Lockyer, C. Patterson, J.C. Schisler. Univ. of North Carolina at Chapel Hill